Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-777-1760
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees6
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions
What is Sophiris Bio's stock symbol?
Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."
How were Sophiris Bio's earnings last quarter?
Sophiris Bio Inc (NASDAQ:SPHS) released its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.02. View Sophiris Bio's Earnings History.
When is Sophiris Bio's next earnings date?
What price target have analysts set for SPHS?
3 brokerages have issued 1 year price targets for Sophiris Bio's shares. Their predictions range from $3.50 to $6.00. On average, they anticipate Sophiris Bio's stock price to reach $4.8333 in the next year. This suggests a possible upside of 398.3% from the stock's current price. View Analyst Price Targets for Sophiris Bio.
What is the consensus analysts' recommendation for Sophiris Bio?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sophiris Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sophiris Bio.
What are Wall Street analysts saying about Sophiris Bio stock?
Here are some recent quotes from research analysts about Sophiris Bio stock:
- 1. Maxim Group analysts commented, "Sophiris’ phase 2B study of topsalysin in localized prostate cancer is approaching its next key data point, effects of a second administration, expected in the next few weeks." (12/6/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $10 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Sophiris Bio Inc." (9/13/2018)
Has Sophiris Bio been receiving favorable news coverage?
News stories about SPHS stock have been trending positive on Monday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sophiris Bio earned a news impact score of 2.5 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for Sophiris Bio.
Are investors shorting Sophiris Bio?
Sophiris Bio saw a decline in short interest during the month of July. As of July 15th, there was short interest totalling 2,007,200 shares, a decline of 9.9% from the June 15th total of 2,228,500 shares. Based on an average trading volume of 173,100 shares, the days-to-cover ratio is currently 11.6 days. Approximately 6.7% of the shares of the stock are short sold. View Sophiris Bio's Current Options Chain.
Who are some of Sophiris Bio's key competitors?
Some companies that are related to Sophiris Bio include Galmed Pharmaceuticals (GLMD), OASMIA PHARMACE/ADR (OASM), Northwest Biotherapeutics (NWBO), Checkpoint Therapeutics (CKPT), Menlo Therapeutics (MNLO), AVEO Pharmaceuticals (AVEO), Entasis Therapeutics (ETTX), Corvus Pharmaceuticals (CRVS), Tocagen (TOCA), Aduro BioTech (ADRO), AgeX Therapeutics (AGE), Aptinyx (APTX), Avenue Therapeutics (ATXI), Eton Pharmaceuticals (ETON) and Aquestive Therapeutics (AQST).
What other stocks do shareholders of Sophiris Bio own?
Who are Sophiris Bio's key executives?
Sophiris Bio's management team includes the folowing people:
- Dr. Lars G. Ekman M.D., Ph.D., Exec. Chairman (Age 69)
- Mr. Randall E. Woods, CEO, Pres & Director (Age 67)
- Mr. Peter T. Slover, Chief Financial Officer (Age 44)
- Dr. Allison J. Hulme, COO, Head of R&D and Director (Age 56)
- Dr. Samuel R. Denmeade, Chief Scientific Officer & Member of the Scientific Advisory Board
Who are Sophiris Bio's major shareholders?
Which institutional investors are selling Sophiris Bio stock?
Which institutional investors are buying Sophiris Bio stock?
How do I buy shares of Sophiris Bio?
Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sophiris Bio's stock price today?
One share of SPHS stock can currently be purchased for approximately $0.9699.
How big of a company is Sophiris Bio?
Sophiris Bio has a market capitalization of $29.31 million. The biopharmaceutical company earns $-6,780,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe.View Additional Information About Sophiris Bio.
What is Sophiris Bio's official website?
How can I contact Sophiris Bio?
Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]
MarketBeat Community Rating for Sophiris Bio (NASDAQ SPHS)
MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe SPHS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHS will underperform the S&P 500 over the long term. You may vote once every thirty days.
